Loading...

NEXTGEN HOMOLOGOUS RECOMBINANT DEFICIENCY PANEL BY NGS, EDTA BLOOD

image not found

 NABL Cap Accredited 
The NextGen HRD Panel by NGS at Metropolis Healthcare evaluates genes involved in the Homologous Recombination Repair (HRR) pathway to detect mutations that may impair DNA repair mechanisms. This test helps identify hereditary and acquired genetic defects linked to breast, ovarian, prostate, and other cancers. Using advanced Next Generation Sequencing, Metropolis Healthcare provides highly accurate genomic insights to support personalized cancer risk assessment and treatment planning. This panel is particularly valuable for evaluating suitability for targeted therapies such as PARP inhibitors

  • 17 Crores+ Samples Processed
  • World Class Technology Labs
  • 25+ Years of Trust & Experience
  • Free Home Collection

Price: Rs. 110,000.00

Sample Type: EDTA Whole Blood

Fasting Not Required


Notes:N8275

Frequently Asked Questions (FAQ's):

 What does the HRD Panel by NGS include?

It analyzes multiple genes involved in the HRR pathway, including BRCA1/2 and other associated genes, to detect pathogenic mutations.

Why is HRD testing important?
It helps identify individuals at higher hereditary cancer risk and guides clinical decisions for targeted therapies like PARP inhibitors.

Who should take this test?
Patients with a personal or family history of breast, ovarian, prostate, or related cancers, or those being evaluated for precision oncology treatment, may benefit.

How does Metropolis Healthcare perform this test?
Metropolis Healthcare uses high-depth Next Generation Sequencing to detect single nucleotide variants, indels, and other HRR pathway defects.

What sample is required for this test?
A blood sample collected in an EDTA tube is used for genomic DNA extraction.

Is any preparation needed?
No fasting or special preparation is required before giving the blood sample.

How soon are the results available?
Metropolis Healthcare provides detailed genetic reports within a clinically appropriate timeframe to support decision-making.

Can this test guide treatment options?
Yes, HRD-positive status can help determine eligibility for PARP inhibitors and other personalized cancer therapies

OUR corporates PARTNER

Feedback

Patient's Testimonials

Trusted by Thousands

OUR Accreditations

OUR Lab